The 2012 Cancer Treatment and Survivorship Statistics report highlights the growing number of cancer survivors in the United States, projected to increase from 13.7 million in 2012 to nearly 18 million by 2022. The most common cancers among males are prostate (43%), colorectal (9%), and melanoma (7%), while among females, they are breast (41%), uterine corpus (8%), and colorectal (8%). Cancer survivors face unique medical and psychosocial challenges, including long-term treatment effects, fear of recurrence, and quality-of-life issues. The article summarizes common treatments, survival rates, and post-treatment concerns, and introduces the National Cancer Survivorship Resource Center, which provides tools for survivors, caregivers, and healthcare professionals. Cancer treatment data is analyzed from the National Cancer Data Base (NCDB) and the SEER-Medicare database. The NCDB includes approximately 70% of all malignant cancers in the U.S., while the SEER-Medicare database combines cancer registry data with claims data to provide a broader picture. Survival rates are calculated using relative survival, which compares cancer patients' survival to the general population. For example, the 5-year relative survival rate for breast cancer has improved from 75.1% to 90.0% between 1975-1977 and 2001-2007, due to improved treatments and earlier diagnosis. Common side effects of treatment include lymphedema, numbness, and impaired fertility. Childhood cancer survivors face unique challenges, including late effects such as second cancers and cognitive impairments. Treatment for childhood cancers involves a combination of surgery, radiation, and chemotherapy, with survival rates improving significantly over the past 30 years. However, survival rates for adolescents and young adults (AYAs) lag behind those for children and older adults, though current 5-year survival rates are similar. For colorectal cancer, survival rates vary by stage, with localized disease having a higher survival rate. Treatment options include surgery, chemotherapy, and radiation therapy. Leukemias and lymphomas have varying survival rates, with some types, like chronic lymphocytic leukemia (CLL), having better survival rates than others. Treatment for melanoma often involves surgery, with high survival rates for localized disease. Prostate cancer is often diagnosed through PSA screening, with treatment options including surgery, radiation, or hormone therapy. Testicular cancer is typically treated with orchiectomy, with high survival rates. Thyroid cancer is often curable with surgery and radioactive iodine therapy. Bladder cancer treatment varies by stage, with options including transurethral resection and cystectomy. Uterine cancer is often treated with surgery, radiation, and hormone therapy, with survival rates varying by stage. The report emphasizes the importance of survivorship care, including long-term follow-upThe 2012 Cancer Treatment and Survivorship Statistics report highlights the growing number of cancer survivors in the United States, projected to increase from 13.7 million in 2012 to nearly 18 million by 2022. The most common cancers among males are prostate (43%), colorectal (9%), and melanoma (7%), while among females, they are breast (41%), uterine corpus (8%), and colorectal (8%). Cancer survivors face unique medical and psychosocial challenges, including long-term treatment effects, fear of recurrence, and quality-of-life issues. The article summarizes common treatments, survival rates, and post-treatment concerns, and introduces the National Cancer Survivorship Resource Center, which provides tools for survivors, caregivers, and healthcare professionals. Cancer treatment data is analyzed from the National Cancer Data Base (NCDB) and the SEER-Medicare database. The NCDB includes approximately 70% of all malignant cancers in the U.S., while the SEER-Medicare database combines cancer registry data with claims data to provide a broader picture. Survival rates are calculated using relative survival, which compares cancer patients' survival to the general population. For example, the 5-year relative survival rate for breast cancer has improved from 75.1% to 90.0% between 1975-1977 and 2001-2007, due to improved treatments and earlier diagnosis. Common side effects of treatment include lymphedema, numbness, and impaired fertility. Childhood cancer survivors face unique challenges, including late effects such as second cancers and cognitive impairments. Treatment for childhood cancers involves a combination of surgery, radiation, and chemotherapy, with survival rates improving significantly over the past 30 years. However, survival rates for adolescents and young adults (AYAs) lag behind those for children and older adults, though current 5-year survival rates are similar. For colorectal cancer, survival rates vary by stage, with localized disease having a higher survival rate. Treatment options include surgery, chemotherapy, and radiation therapy. Leukemias and lymphomas have varying survival rates, with some types, like chronic lymphocytic leukemia (CLL), having better survival rates than others. Treatment for melanoma often involves surgery, with high survival rates for localized disease. Prostate cancer is often diagnosed through PSA screening, with treatment options including surgery, radiation, or hormone therapy. Testicular cancer is typically treated with orchiectomy, with high survival rates. Thyroid cancer is often curable with surgery and radioactive iodine therapy. Bladder cancer treatment varies by stage, with options including transurethral resection and cystectomy. Uterine cancer is often treated with surgery, radiation, and hormone therapy, with survival rates varying by stage. The report emphasizes the importance of survivorship care, including long-term follow-up